Abstract
1 Observations were made in five healthy subjects who exercised before and 2, 3, 6, 8 and 24 h after the oral administration on separate occasions of 160 mg oxprenolol, 160 mg slow release oxprenolol, 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide and placebo. Blood samples were obtained before and at 1, 2, 3, 6, 8, 12 and 24 h after drug administration and assayed for oxprenolol concentration. 2 The three formulations produced maximum reductions of 29% in the exercise tachycardia 3 to 6 h after drug administration. At 24 h the effects of the three preparations were not significantly different from placebo. 3 There were no significant differences in the plasma concentrations produced by the three formulations during the 24 h period. 4 These observations suggest that the slow release formulations of oxprenolol should be given twice daily to maintain cardiac beta-adrenoceptor blockade throughout a period of 24 h.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bobik A., Jennings G. L., Korner P. I., Ashley P., Jackman G. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Br J Clin Pharmacol. 1979 Jun;7(6):545–549. doi: 10.1111/j.1365-2125.1979.tb04640.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Douglas-Jones A. P., Baber N. S., Lee A. Once daily propranolol in the treatment of mild to moderate hypertension: a dose range finding study. Eur J Clin Pharmacol. 1978 Nov 27;14(3):163–166. doi: 10.1007/BF02089954. [DOI] [PubMed] [Google Scholar]
- Frick M. H., Kala R. Once daily versus twice daily beta-blockers: effects on arrhythmias and hypertension. Lancet. 1980 Sep 13;2(8194):588–588. doi: 10.1016/s0140-6736(80)92020-6. [DOI] [PubMed] [Google Scholar]
- Harron D. W., Shanks R. G. Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). Br J Clin Pharmacol. 1981 May;11(5):518–520. doi: 10.1111/j.1365-2125.1981.tb01160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leahey W. J., Neill J. D., Varma M. P., Shanks R. G. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol. 1980 Jun;17(6):419–424. doi: 10.1007/BF00570158. [DOI] [PubMed] [Google Scholar]
- Leahey W. J., Neill J. D., Varma M. P., Shanks R. G. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol. 1980 Jan;9(1):33–40. doi: 10.1111/j.1365-2125.1980.tb04793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Marshall A. J., Barritt D. W., Pocock J., Heaton S. T. Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension. Lancet. 1977 Feb 5;1(8006):271–274. doi: 10.1016/s0140-6736(77)91822-0. [DOI] [PubMed] [Google Scholar]
- Petrie J. C., Galloway D. B., Webster J., Simpson W. T., Lewis J. A. Atenolol and bendrofluazide in hypertension. Br Med J. 1975 Oct 18;4(5989):133–135. doi: 10.1136/bmj.4.5989.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petrie J. C., Jeffers T. A., Robb O. J., Scott A. K., Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. Br Med J. 1980 Jun 28;280(6231):1573–1574. doi: 10.1136/bmj.280.6231.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reybrouck T., Amery A., Fagard R., Jousten P., Lijnen P., Meulepas E. Beta-blockers: once or three times a day? Br Med J. 1978 May 27;1(6124):1386–1388. doi: 10.1136/bmj.1.6124.1386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waal-Manning H. J., Spears G. F. Experience with a slow-release formulation of oxprenolol. N Z Med J. 1978 Apr 12;87(609):245–246. [PubMed] [Google Scholar]